Documenti analoghi

• Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period
  di: Kazuma Mori, et al.
  Pubblicazione: (2024)
• Association of metabolic dysfunction‐associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study
  di: Masahiro Sogabe, et al.
  Pubblicazione: (2024)
• Lower hepatocellular carcinoma surveillance in metabolic dysfunction‐associated steatotic liver disease: Impact on treatment eligibility
  di: Connor Henry‐Blake, et al.
  Pubblicazione: (2024)
• Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease
  di: Yi‐Ting Chen, et al.
  Pubblicazione: (2024)
• Exploring a Subpopulation of MASLD Associated With New Onset of CKD Using Supervised Clustering Techniques
  di: Itaru Hosaka, et al.
  Pubblicazione: (2026)